Full-Time
Confirmed live in the last 24 hours
Develops medical devices for vascular conditions
$143.6k - $180.6kAnnually
Senior, Expert
Company Historically Provides H1B Sponsorship
Alameda, CA, USA
The job is onsite in Alameda, CA.
You match the following Penumbra Inc's candidate preferences
Employers are more likely to interview you if you match these preferences:
Penumbra Inc. creates medical devices for treating neurovascular and peripheral vascular conditions, including products like the Penumbra System for stroke treatment and the Indigo System for peripheral diseases. Their devices assist healthcare professionals in hospitals and clinics across Europe and the Americas. Penumbra stands out from competitors by focusing on specialized devices and investing in research and development to meet the evolving needs of the medical community. The company's goal is to provide high-quality solutions that improve patient outcomes in vascular care.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$116.7K
Headquarters
Alameda, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity
The Society of Interventional Radiology (SIR) Foundation, The VIVA Foundation and Penumbra, today announced the launch of the EMBOLIZE trial, a first-of-its-kind prospective, randomised controlled trial studying the effects of ovarian vein embolization (OVE) and pelvic vein embolization in reducing pain in women experiencing chronic pelvic pain due to pelvic venous disease (PeVD).
ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. Event: 43rd Annual J.P. Morgan Healthcare ConferenceDate: Monday, January 13, 2025Time: 6:00pm ET/3:00pm PT
ALAMEDA, Calif., Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. Event: Piper Sandler 36th Annual Healthcare ConferenceDate: Wednesday, December 4, 2024Time: 8:00am ET/5:00am PT. A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event
Penumbra will lay off 71 people working in its Immersive Healthcare business, according to a California Worker Adjustment and Retraining Notification notice obtained by MedTech Dive.